8. Summary
Although pMDIs are currently the most widely used aerosol delivery devices, challenges associated with pMDIs have meant that major drug classes and their combinations are not available for this inhaler type. As a result, there is a need for alternative formulation and delivery approaches. In its fundamental form, cosuspension delivery technology is a simple and versatile formulation platform for pMDIs. The platform uses drug crystals, which are the naturally stable form of a drug, and phospholipid porous particles, which are naturally buoyant low-density particles, together. This approach allows the potential to formulate drugs with a wide range of pharmacological properties, physicochemical attributes, and doses, whether alone or in combinations. Thus, co-suspension delivery technology provides an opportunity to combine multiple drugs with highly variable characteristics in the same pMDI device while maintaining uniformity and suspension stability, thereby overcoming the variability associated with conventional formulations. Consistent delivery of small and large molecules can now be contemplated from one inhaler. This formulation approach has shown the ability to target all regions of lungs consistently. In addition, the co-suspension delivery technology formulation has been shown to have consistent drug delivery across various pMDI patient-use scenarios. By solving some of the longest-standing challenges with pMDI-based drug delivery, the co-suspension delivery technology has the potential to enable development of multiple therapies in one inhaler type and increase patient adherence to therapy.
